CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
- PMID: 38861351
- PMCID: PMC11375260
- DOI: 10.1182/bloodadvances.2024013044
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
Abstract
Multiple chimeric antigen receptor (CAR) T-cell therapies are US Food and Drug Administration-approved, and several are under development. Although effective for some cancers, toxicities remain a limitation. The most common toxicities, that is, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, are well described. With increasing utilization, providers worldwide are reporting other emergent and often complicated toxicities. Given the evolving toxicity profiles and urgent need to catalog these emerging and emergent CAR T-cell toxicities and describe management approaches, the American Society of Hematology Subcommittee on Emerging Gene and Cell Therapies organized the first scientific workshop on CAR T-cell toxicities during the annual society meeting. The workshop functioned to (1) aggregate reports of CAR T-cell emergent toxicities, including movement disorders after B-cell maturation antigen CAR T cell, coagulation abnormalities, and prolonged cytopenia; (2) disseminate bedside-to-bench efforts elucidating pathophysiological mechanisms of CAR T-cell toxicities, including the intestinal microbiota and systemic immune dysregulation; and (3) highlight gaps in the availability of clinical tests, such as cytokine measurements, which could be used to expand our knowledge around the monitoring of toxicities. Key themes emerged. First, although clinical manifestations may develop before the pathophysiologic mechanisms are understood, they must be studied to aid in the detection and prevention of such toxicities. Second, systemic immune dysregulation appears to be central to these emergent toxicities, and research is needed to elucidate the links between tumors, CAR T cells, and microbiota. Finally, there was a consensus around the urgency to create a repository to capture emergent CAR T-cell toxicities and the real-world management.
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Similar articles
-
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.Drug Saf. 2025 Jul;48(7):719-737. doi: 10.1007/s40264-025-01538-5. Epub 2025 Mar 19. Drug Saf. 2025. PMID: 40108072 Free PMC article. Review.
-
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w. Semin Immunopathol. 2024. PMID: 39012374 Free PMC article. Review.
-
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.Int J Mol Sci. 2024 Jun 29;25(13):7174. doi: 10.3390/ijms25137174. Int J Mol Sci. 2024. PMID: 39000281 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. Cochrane Database Syst Rev. 2021. PMID: 34515338 Free PMC article.
Cited by
-
Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305. Blood Adv. 2024. PMID: 39718780 Free PMC article. No abstract available.
-
Neurological complications of CAR T cell therapy for cancers.Nat Rev Neurol. 2025 Aug;21(8):422-431. doi: 10.1038/s41582-025-01112-8. Epub 2025 Jun 25. Nat Rev Neurol. 2025. PMID: 40562951 Review.
-
CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome.Med Oncol. 2025 Apr 24;42(6):179. doi: 10.1007/s12032-025-02735-z. Med Oncol. 2025. PMID: 40272709 Review.
-
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia.Transplant Cell Ther. 2025 Aug;31(8):551-564. doi: 10.1016/j.jtct.2025.05.003. Epub 2025 May 20. Transplant Cell Ther. 2025. PMID: 40398620
-
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025. Front Immunol. 2025. PMID: 40612954 Free PMC article. Review.
References
-
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. - PubMed
-
- Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212–2221. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials